Press

2024-05-17

Interim Report First Quarter 2024, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the first quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million) R&D expenses amounted to SEK 11,4 million (SEK 15,2 million) Operating loss for the quarter amounted to...

Read More
2024-05-16

Kancera provides operational update regarding the KANDOVA study and reports increased patient recruitment

In connection with the upcoming Interim Report for the first quarter 2024, Kancera AB (publ) provides an operational update regarding KANDOVA, a combined phase Ib/IIa study of KAND567 in ovarian cancer, and reports that: The patient recruitment pace has...

Read More
2024-05-08

Kancera appoints new Chief Scientific Officer and extends management team

Kancera AB (publ) today announces that Robert Edfors is appointed as new Chief Scientific Officer and Senior Vice President Clinical Development and that the management team is extended with two new positions.

Read More
2024-05-03

Kancera meets the primary objectives of the KAND145 clinical phase I study

Kancera AB (publ) today reports positive results from the clinical phase I study with KAND145 in healthy subjects and that the primary objectives of the study were met: KAND145 is safe and tolerable at maximum exposure when administered as...

Read More
2024-03-20

Kancera announces the outcome of the company’s rights issue

The board of directors of Kancera AB (”Kancera” or the ”Company”), hereby announces the outcome of the Company's rights issue of shares with preferential rights for the Company's existing shareholders and which was covered by subscription and guarantee commitments...

Read More
2024-03-01

Kancera publishes prospectus in connection with the company’s rights issue

Kancera AB (”Kancera” or the ”Company”) announced on February 23, 2024, that the board of directors has resolved to carry out a new issue of shares with preferential rights for existing shareholders in the Company, corresponding to approximately SEK...

Read More
2024-02-23

Kancera resolves on a rights issue of approximately SEK 121.9 million

The board of directors of Kancera AB (”Kancera” or the ”Company”), has today, based on the issue authorization from the annual general meeting held on May 25, 2023, resolved on a new share issue with preferential rights for the...

Read More
2024-02-23

Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851

The period in brief – financial summary for the fourth quarter Net sales amounted to SEK 0 million (SEK 0). R&D expenses amounted to SEK 17,1 million (SEK 11,6 million). Operating income amounted to SEK -18,5 million (SEK -14,0...

Read More
2024-02-23

Kancera signs license agreement and obtains global commercial rights to the results from the FRACTAL study

In connection with the interim report for the fourth quarter 2023, Kancera AB (publ) today provides a general operational update and reports that the company has signed a license agreement with the University of Newcastle. Through this agreement, Kancera...

Read More
2024-02-06

Kancera presents the statistical analysis of top line data from the FRACTAL study

Kancera AB (Kancera) has previously reported the initial top line results from the FRACTAL study and today Kancera presents the statistical analyses that confirm that: the primary objective was met, by showing that KAND567 was safe and well tolerated...

Read More